Clover Biopharmaceuticals (HKSE:02197) Buyback Yield %: -0.02 (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02197 Clover Biopharmaceuticals Ltd HKSE:02197
28 GF Score
Price HK$2.02
! 3 Warning Signs
View Full Analysis

What is Clover Biopharmaceuticals Buyback Yield %?

Clover Biopharmaceuticals HKSE:02197 -0.98% 28 Buyback Yield % is -0.02 as of Sep. 03, 2026. GuruFocus rates HKSE:02197 with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 699 Biotechnology companies, Clover Biopharmaceuticals ranks better than 86.41% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Clover Biopharmaceuticals's current buyback yield was -0.02%.

Clover Biopharmaceuticals Buyback Yield % Related Terms

Clover Biopharmaceuticals Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Clover Biopharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clover Biopharmaceuticals Buyback Yield % Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -13.75 -15.12 -0.01 0.00 -0.02

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 0.00 0.00 -0.02

HKSE:02197 vs VRTX, REGN, MRNA: Buyback Yield % Comparison

For the Biotechnology subindustry, Clover Biopharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clover Biopharmaceuticals Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Buyback Yield % falls into.


HKSE:02197
28GF Score
Clover Biopharmaceuticals Ltd HKSE:02197
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clover Biopharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Clover Biopharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0.535) / 3036.93858
=-0.02%

Clover Biopharmaceuticals's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0.535) / 3036.93858
=-0.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -0.02 mean?
Clover Biopharmaceuticals (HKSE:02197) has a Buyback Yield % of -0.02 as of Sep. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Clover Biopharmaceuticals and its competitors. According to the industry distribution chart, Clover Biopharmaceuticals ranks #95 out of 699 companies in the Biotechnology industry, placing it in the top 13.6%.
Is Clover Biopharmaceuticals' Buyback Yield % too high?
Clover Biopharmaceuticals' current Buyback Yield % is -0.02. Based on the distribution chart, Clover Biopharmaceuticals ranks #95 out of 699 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clover Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Clover Biopharmaceuticals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clover Biopharmaceuticals ranks #95 out of 699 companies for Buyback Yield %. This places Clover Biopharmaceuticals in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Clover Biopharmaceuticals and its competitors. Clover Biopharmaceuticals's current Buyback Yield % is -0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clover Biopharmaceuticals stock overvalued right now?
Clover Biopharmaceuticals (HKSE:02197) has a current Buyback Yield % of -0.02. The current Buyback Yield % is -0.02. Clover Biopharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Clover Biopharmaceuticals (HKSE:02197), the current Buyback Yield % is -0.02 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clover Biopharmaceuticals Business Description

Address No. 758 West Nanjing Road, Room 1901, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to unleashing the power of vaccines to save lives and improve health around the world. The leverage the proprietary Trimer-Tag technology platform to conduct R&D for vaccines that can fulfill unmet needs, with a focus on building a respiratory vaccine franchise to reduce the burden of vaccine-preventable diseases. The Group has only one operating segment, which is the research and development, manufacturing, and commercialisation of vaccines. Geographically, the company earns revenue from Mainland China and Korea.
28GF Score

Get the complete analysis for HKSE:02197

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.02
Price